Literature DB >> 15546258

Chemokine levels in the jugular venous blood of migraine without aura patients during attacks.

Paola Sarchielli1, Andrea Alberti, Luana Vaianella, Laura Pierguidi, Alessandro Floridi, Giovanni Mazzotta, Ardesio Floridi, Virgilio Gallai.   

Abstract

OBJECTIVE: To investigate changes in the levels of calcitonin gene-related peptide and its intracellular messenger cyclic adenosine monophosphate in serial samples of internal jugular blood taken from migraine patients without aura assessed during attacks, and to assess their relationship with the levels of IL-8, MCP-1, and RANTES in the same samples.
BACKGROUND: Calcitonin gene-related peptide, the marker of trigeminovascular activation, is released in both the internal and external jugular venous blood of migraine patients during attacks. Experimental evidence demonstrated that when released from C-type sensory neurons in inflammatory pain models, it differentially induced expression of neutrophil chemotactic chemokine IL-8, but not monocyte chemotactic chemokine MCP-1 or lymphocyte chemotactic chemokine RANTES. These chemokines were never investigated in migraine. DESIGN/
METHODS: Eight migraine without aura patients were admitted to the hospital during the attacks. Internal jugular venous blood samples were taken immediately after catheter insertion, at the 1st, 2nd, and 4th hours after attack onset, and within 2 hours from its cessation. The levels of the sensory neuropeptide calcitonin gene-related peptide and the messenger cyclic adenosine monophosphate were measured by RIA method, and those of IL-8, MCP-1, and RANTES were measured by ELISA method.
RESULTS: Higher calcitonin gene-related peptide levels were found in the internal jugular venous blood of migraine without aura patients compared with the time of catheter insertion (ANOVA: P<.0001) with a peak at the first hour (52.6+/-9.2 ng/mL). A transient increase in IL-8 was observed at the 2nd and 4th hours (P<.01 and P<.002, respectively), whereas no changes in the levels of MCP-1 and RANTES were found at any time of the study. The increase in IL-8 was accompanied by a parallel increase in cyclic adenosine monophosphate.
CONCLUSIONS: The present study confirms previous findings of an increase in calcitonin gene-related peptide in internal jugular venous blood of migraine without aura patients during attacks. The transient increase in the levels of IL-8 concurs with the results of recent experimental research showing a calcitonin gene-related peptide-induced activation of IL-8 gene expression, but not RANTES and MCP-1, via the transcriptional factor AP-2, which mediates transduction in response to cyclic adenosine monophosphate. Although IL-8 is transiently increased during migraine attacks, an accumulation of leukocytes secondary to neurogenic inflammation is unlikely, as it is for other inflammatory events, because they are self limiting. Other events, including nitric oxide production, may contribute to counteract meningeal transvascular leukocyte migration during migraine attacks, as suggested by the model of sterile inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546258     DOI: 10.1111/j.1526-4610.2004.04189.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  14 in total

Review 1.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

2.  Identification of cytokines and signaling proteins differentially regulated by sumatriptan/naproxen.

Authors:  Carrie V Vause; Paul L Durham
Journal:  Headache       Date:  2011-12-08       Impact factor: 5.887

Review 3.  Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF.

Authors:  Rashid Giniatullin; Andrea Nistri; Elsa Fabbretti
Journal:  Mol Neurobiol       Date:  2008-05-06       Impact factor: 5.590

4.  Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.

Authors:  Vincent T Martin; Jeanne Ballard; Michael P Diamond; Lisa K Mannix; Frederick J Derosier; Shelly E Lener; Alok Krishen; Susan A McDonald
Journal:  J Womens Health (Larchmt)       Date:  2014-02-28       Impact factor: 2.681

5.  Increased interictal serum levels of CXCL8/IL-8 and CCL3/MIP-1α in migraine.

Authors:  Halina Duarte; Antonio L Teixeira; Natália P Rocha; Renan B Domingues
Journal:  Neurol Sci       Date:  2014-09-06       Impact factor: 3.307

6.  Increased asymmetric dimethylarginine and nitric oxide levels in patients with migraine.

Authors:  Ertugrul Uzar; Osman Evliyaoglu; Gülten Toprak; Abdullah Acar; Yavuz Yucel; Tugba Calisir; Mehmet Ugur Cevik; Nebahat Tasdemir
Journal:  J Headache Pain       Date:  2011-02-27       Impact factor: 7.277

7.  Associations between potential inflammatory properties of the diet and frequency, duration, and severity of migraine headaches: a cross-sectional study.

Authors:  Seyed Mojtaba Ghoreishy; Gholamreza Askari; Hamed Mohammadi; Marilyn S Campbell; Fariborz Khorvash; Arman Arab
Journal:  Sci Rep       Date:  2022-02-21       Impact factor: 4.379

Review 8.  Chemokines and Pain in the Trigeminal System.

Authors:  Oscar O Solis-Castro; Natalie Wong; Fiona M Boissonade
Journal:  Front Pain Res (Lausanne)       Date:  2021-07-09

9.  TNFα levels and macrophages expression reflect an inflammatory potential of trigeminal ganglia in a mouse model of familial hemiplegic migraine.

Authors:  Alessia Franceschini; Sandra Vilotti; Michel D Ferrari; Arn M J M van den Maagdenberg; Andrea Nistri; Elsa Fabbretti
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

10.  A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine.

Authors:  Yuen H Kwok; James E Swift; Parisa Gazerani; Paul Rolan
Journal:  J Pain Res       Date:  2016-10-31       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.